Top Markets
Coin of the day
Medesis Pharma S.A. Medesis Pharma S.A.

Medesis Pharma S.A.

ALMDP
株式のランク #37493
Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development... Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to creating orally delivered molecular drug therapies aimed at critical medical conditions lacking effective treatments. The company's pipeline features several innovative compounds, including NanoLithium (NP03), which is currently undergoing clinical trials for Alzheimer's disease, and NanosiRNA DH, targeting Huntington's Disease. Medesis Pharma also develops NU01 Plutonium and NU02 Cesium for nuclear decorporation, alongside NP02 – NanoManganese, a radioprotection medication designed for individuals exposed to radiation from nuclear incidents. Furthermore, their portfolio encompasses NanosiRNA COVID-19, an antiviral solution for various viral infections, and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for oncological applications. Established in 2003, the enterprise operates from its headquarters in Montpellier, France.
株価
$0.38207938
最終同期: 2025-04-07
時価総額
$1.67M
変化(1日)
-0.39%
変化(1年)
0.00%
FR
取引 Medesis Pharma S.A. (ALMDP)

カテゴリー

Medesis Pharma S.A.(ALMDP)の利益
2026 時点の利益 TTM: 0
Medesis Pharma S.A. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Medesis Pharma S.A. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益